BRUSSELS: Philadelphia generic pharmaceutical manufacturer Lannett Co. Inc. said this week it was moving forward with its planned $1.2 billion acquisition of a rival, despite that rival losing a major customer.
Lannett (NYSE: LCI) in September entered into a deal to buy Princeton-based Kremers Urban Pharmaceuticals Inc., a specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB SA of Belgium, in a transaction expected to close before the end of the year.
The Chinese central bank announced it will inject 1,200 billion yen (156 billion euros) into the Chinese economy, which is...
Portugal will introduce a flat tax rate on the income of foreign pensioners, rolling back a generous tax break which...
Among others, the Flemish contingent includes MoNoA, a product that raises your body temperature and analyses your movements to gauge...
A Belgian customs officer was suspended last week after the Federal Public Service Finance department discovered that the individual concerned...
